Litcius/Paper detail

175P A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC)

Yanhong Gu, X. Chen, D. Wang, Man-Hua Ding, Lijun Xue, Fuxi Zhen, Jing Xu, M. Wang, Yao Li, Nana Sun, C. Liu, Lingyan Xu, Y. Wang, Jiwei Luo

2020Annals of Oncology31 citationsDOI

Topics & Concepts

MedicineEsophagectomyOncologyEsophageal cancerChemotherapyCisplatinInternal medicineChemoradiotherapyPaclitaxelStage (stratigraphy)Neoadjuvant therapyCancerSurgeryBreast cancerBiologyPaleontologyEsophageal Cancer Research and TreatmentCancer Immunotherapy and BiomarkersGastric Cancer Management and Outcomes
175P A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC) | Litcius